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Ceramide metabolism determines glioma cell resistance to
chemotherapy
Abstract
Tumor cell resistance to chemotherapy constitutes a major problem in the treatment of malignant
tumors. We here investigated the role of ceramide metabolism for the resistance of glioma cells to
treatment with the chemotherapeutic drug, gemcitabine. Gemcitabine triggers a marked release of
ceramide in drug-sensitive cells, while glioma cells that are resistant to gemcitabine, fail to accumulate
ceramide. While the release of ceramide is very similar in gemcitabine-sensitive and resistant glioma
cells upon stimulation, resistant glioma cells rapidly consume ceramide upon gemcitabine treatment or
exogenous sphingomyelinase stimulation. Pharmacologic or genetic inhibition of glucosyltransferases
prevents ceramide consumption in resistant cells and restores sensitivity of resistant glioma cells to
gemcitabine. These data suggest that glioma cell resistance to at least some chemotherapeutic drugs is
mediated by rapid consumption of ceramide to prevent cell death.
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 ABSTRACT 
 
Tumor cell resistance to chemotherapy constitutes a major problem in the treatment of 
malignant tumors. Here, we investigated the role of the ceramide metabolism for the 
resistance of glioma cells to treatment with the chemotherapeutic drug gemcitabine. 
Gemcitabine triggers a marked release of ceramide in drug-sensitive cells, while glioma cells 
that are resistant to gemcitabine, fail to accumulate ceramide. While the release of ceramide is 
very similar in gemcitabine-sensitive and resistant glioma cells upon stimulation, resistant 
glioma cells rapidly consume ceramide upon gemcitabine treatment or exogenous 
sphingomyelinase stimulation. Pharmacologic and genetic inhibition of glucosyltransferases 
prevents ceramide consumption in resistant cells and restores sensitivity of resistant glioma 
cells to gemcitabine. These data suggest that glioma cells are able to develop resistance to at 
least some chemotherapeutic drugs by rapid consumption of ceramide to prevent cell death.  
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INTRODUCTION 
 
Malignant gliomas are the most common primary brain tumors in adults. The most aggressive 
form of glioma, glioblastoma multiforme, is characterized by a poor prognosis for the patient, 
with a median survival of only approximately 12 months. Due to a predominant tendency to 
invade surrounding tissue, gliomas cannot be resected completely and require, thus, chemo- 
and radiotherapy in addition to surgery. Despite development of new drugs, one of the main 
obstacles in successful treatment of cancer remains, however, the chemotherapy resistance of 
tumor cells.  
 
Numerous studies focused on characterizing molecular mechanisms mediating resistance of 
cancer cells to therapy. In many types of cancer, a prevalent role has been attributed to drug 
efflux pumps, which can actively transport chemotherapy agents out of the cells, thus 
rendering them ineffective and leading to so-called multidrug resistance (MDR) (x). Several 
studies suggested ABC transporters to mediate glioma cell resistance to various anticancer 
drugs (x). In particular, expression of MRP1 has been found to be significantly increased in 
grade III and IV gliomas, compared to low grade tumors (x). Similarly, ABCG2, a transporter 
which can efflux more than 20 chemotherapeutic drugs (x) had a higher expression in high 
grade gliomas (x). 
A growing body of evidence suggests that alterations in the apoptotic pathways of gliomas are 
also important modulators of the response to therapy (x). Apoptosis can be induced via two 
major pathways, namely the extrinsic (death receptor-initiated) or the intrinsic (mitochondria-
initiated) pathway (x). The two pathways converge on activation of caspase-3 and 
subsequently on other proteases and nucleases that drive the terminal events of apoptosis. In 
turn, every step in the apoptotic cascade is monitored and controlled by certain pro-survival 
signals provided by families of anti-apoptotic molecules such as NF-κB, PI3K/Akt, Bcl-2 and 
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IAPs (x). An up-regulation of the anti-apoptotic pathways in glioma cells has been described 
by many studies, and was proposed to be one of the main mechanisms responsible for glioma 
resistance to therapy. For instance, it has been shown that recurrent glioblastomas exhibit 
upregulation of the anti-apoptotic proteins Bcl-2 and Bcl-xL (x).  More recently the anti-
apoptotic Bcl-2 family member Bcl-2-like-12 (Bcl2L12) has been shown to be highly 
expressed in almost every glioblastoma sample examined and knocking down this protein 
resulted in sensitization to chemotherapeutic agents (x).  Similarly, the IAP family members 
XIAP, c-IAP1, c-IAP2, and Bruce (Apollon) have been shown to be highly expressed in a 
number of malignant glioma cell lines (x). Many survival stimuli act via activation of the 
PI3K/Akt pathway (x) and PI3K/Akt is known to be induced by growth factors and their 
receptors, such as EGFR or PDGFR, which were found to be overexpressed in many gliomas 
(x).  
 
Over the last years, many groups demonstrated the critical role of sphingolipids as modulators 
of cellular death/survival pathways (for review see xx). A central role in apoptosis triggered 
by many stimuli currently used in cancer therapy has been attributed to ceramide generated 
via the acid sphingomyelinase pathway (xx). Stimulation with members of the TNF family of 
ligands, such as TRAIL or CD95, leads to acid sphingomyelinase activation and formation of 
ceramide platforms onto the plasma membrane, which serve to cluster death receptors and, 
thus, to induce apoptosis (x). The acid sphingomyelinase/ceramide pathway was proved to be 
involved also in cellular responses to γ-irradiation, and acid sphingomyelinase-deficient 
endothelial cells were resistant to irradiation doses of up to 50 Gy (x). Several studies 
proposed acid sphingomyelinase and ceramide as mediators of chemotherapy-induced cell 
death. Morita and co-workers showed that oocytes derived from acid-sphingomyelinase-
deficient mice were resistant to doxorubicin stimulation (x), while other studies revealed 
activation of acid sphingomyelinase and subsequent ceramide levels increase upon treatment 
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of tumor cells with cisplatin (x). Our group has recently demonstrated that overexpression of 
acid sphingomyelinase sensitizes transfected cells to doxorubicin and gemcitabine-induced 
cell death via increasing cellular ceramide levels (x). While generation and accumulation of 
ceramide triggers cell death in stimulated cells, a decrease in ceramide levels seems to lead to 
cellular survival. This was shown to occur via a direct removal of ceramide inhibitory effects 
on anti-apoptotic molecules, such as Bcl-2 (x) or via pro-survival mechanisms triggered by 
metabolites of ceramide consumption (x). 
 
In the present study we investigated whether glioma resistance to gemcitabine is mediated by 
an altered ceramide metabolism of resistant cells in response to chemotherapy. We 
demonstrate that gemcitabine treatment leads to ceramide accumulation and cell death in the 
bulk population of glioma cells, but not in cells selected for resistance after single exposure to 
clinically achievable concentrations of gemcitabine. Our studies demonstrate that the resistant 
glioma population rapidly consumes ceramide upon gemcitabine or exogenous 
sphingomyelinase stimulation. Pharmacologic and genetic studies suggest that 
glucosyltransferase-mediated ceramide consumption is responsible for resistance of these 
cells to chemotherapy and inhibition of glucosyltransferases restores sensitivity of resistant 
glioma cells to gemcitabine. 
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 MATERIALS and METHODS 
 
Cells  
The mouse astrocytoma cell line SMA 560 has been previously described (x). 105 SMA 560 
cells were injected i.m. into the leg of a VM/Dk mouse to insure tumorigenicity. The tumor 
was excised 14 days later and prepared into single cell suspension by enzymatic digestion 
with 1 mg/ml Collagenase A (Roche, Mannheim, Germany) for 1 hour, at 37°C. The resulting 
cells, designated SMA, were cultured and maintained in DMEM (Dulbecco's Modified 
Eagle's Medium)  supplemented with 10% fetal calf serum (FCS), 10 mM HEPES (pH 7.4), 2 
mM L-Glutamine, 1 mM sodium pyruvate, 100 mM nonessential amino acids, 100 Units/ml 
penicillin and 100 mg/ml streptomycin (all from Invitrogen, Karlsruhe, Germany). 
 
Reagents and antibodies 
Monoclonal anti-ceramide antibodies were obtained from Glycobiotech (Kuekels, Germany). 
Anti-Tim23 antibodies were from BD Pharmingen (San Diego, CA, USA), anti-Bax 
antibodies were obtained from Upstate (Lake Placid, NY, USA). All fluorescent secondary 
antibodies (Cy3-donkey anti-mouse IgM, Cy5-donkey anti-mouse IgM, Cy3- donkey anti-
rabbit IgG and FITC-donkey anti-mouse IgG) were from Jackson Immunoresearch (West 
Grove, PA, USA). PPMP (DL-threo-1-Phenyl-2-palmitoylamino-3-morpholino-1-propanol), 
NOE (N-Oleoylethanolamine) and exogenous sphingomyelinase were from Sigma (Sigma, St. 
Louis, MO, USA). 
 
Immunofluorescence assays 
Cells were treated as indicated, washed once in HEPES/Saline (H/S; 132 mM NaCl, 20 mM 
HEPES (pH 7.4), 5 mM KCl, 1 mM CaCl2, 0.7 mM MgCl2, 0.8 mM MgSO4) and 
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fixed/permeabilized for 20 min at room temperature using BD Cytofix/Cytoperm kit (BD 
Biosciences, San Diego, CA, USA). Cells were then incubated with the indicated primary 
antibodies for 45 min at room temperature. Anti-ceramide antibodies were diluted 1:100. 
Anti-Bax and anti-Tim23 antibodies were diluted 1:250. The samples were washed again and 
incubated with the respective fluorescent secondary antibodies for 30 min at room 
temperature. All secondary antibodies were diluted 1:1000. Cells were finally washed two 
times with H/S. Samples stained for ceramide were analysed employing a FACS Calibur flow 
cytometer (Beckton Dickinson, San Jose, CA, USA). Samples stained for Bax and Tim23 
were mounted in Fluoprep (BioMerieux, France) and analysed by laser scanning microscopy 
using a LEICA TSP2 module linked to a LEICA DMIRE 2 microscope (Leica, Germany). 
 
Acid sphingomyelinase activity 
Acid sphingomyelinase activity was measured as previously described (Gulbins & Kolesnick, 
2000). Tumor cells were incubated with 100 nM gemcitabine for the indicated times. The 
cells were then scraped and lysed in a buffer containing 0.1% Triton X-100 and 50 mM 
sodium acetate (pH 5.0) for 10 min on ice followed by three sonication cycles. The cell 
lysates were incubated with 0.05 mCi per sample of [14C]-labeled sphingomyelin (2 
GBq/mmol; MP-Biomedicals, Irvine, CA, USA) for 30 min at 37°C. To this end, the substrate 
[14C]-labeled sphingomyelin was dried under vacuum, resuspended in 0.1% Triton X-100 and 
50 mM sodium acetate (pH 5.0) and sonicated in a bath sonicator to promote the formation of 
liposomes. The reaction was terminated by extraction in CHCl3:CH3OH (2:1, v/v). The 
samples were centrifuged for 10 min, maximum speed and an aliquot of the aqueous phase 
was measured by liquid scintillation counting to quantify released phosphorylcholine. This 
method results in hydrolysis of less than 20% (range of 2% to maximal 20%) of [14C]-labeled 
sphingomyelin and is therefore suitable for a broad range of cells. 
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Apoptosis assays 
Following stimulation, cells were stained with FITC-Annexin V alone or FITC-Annexin V 
and propidium iodide according to the manufacturer’s instructions (Roche Molecular 
Biochemicals). Quantification was performed employing a FACS Calibur flow cytometer 
(Beckton Dickinson, San Jose, CA, USA). 
 
Ceramide measurement 
To determine ceramide by the DAG-kinase assay, cells were extracted in CHCl3:CH3OH:1 N 
HCl (100:100:1, v/v/v), the organic phase was collected, dried and resuspended in 20 µl of a 
detergent solution consisting of 7.5% (w/v) n-octylglucopyranoside and 5 mM cardiolipin in 1 
mM DETAPAC (diethylenetriamine pentaacetic acid). To promote the formation of micelles, 
samples were sonicated for 10 min in a bath sonicator. To start the kinase reaction 50 µl of a 
buffer consisting of 100 mM imidazole/HCl (pH 6.6), 100 mM NaCl, 25 mM MgCl2, 2 mM 
EGTA, 2.8 mM DTT, 5 mM ATP, 10 µCi [32P]gamma-ATP and 10 µl DAG kinase (xx 
Claudia please give enzyme units/ml xx) (Calbiochem/Merck, Darmstadt, Germany) pre-
diluted in 1 mM DETAPAC (pH 6.6), 100 mM imidazole/HCl) were added and the samples 
were incubated for 30 min at room temperature. The kinase reaction was stopped by 
extraction of the samples with 1 ml CHCl3:CH3OH:1 N HCl (100:100:1, v/v/v), 170 µl 
buffered saline solution (135 mM NaCl, 1.5 mM CaCl2, 0.5 mM MgCl2, 5.6 mM Glucose, 10 
mM HEPES, pH 7.2) and 30 µl of a 100 mM EDTA-solution. The lower phase was collected, 
dried and dissolved in 20 µl CHCl3:CH3OH (1:1, v/v). Lipids were separated on a Silica G60 
TLC plate (Merck, Darmstadt, Germany) with a buffer containing Chloroform, Acetone, 
Methanol, Acetic Acid and H2O (50:20:15:10:5, v/v/v/v/v). The plates were dried and 
analysed using a FLA-3000 Phospho-Imager (Fujifilm Life Sciences, Düsseldorf, Germany).  
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Soft-agar clonogenic assay 
96-well plates were coated with 1% High-Gelling Agarose (Sigma, St. Louis, MO, USA). 
Equal numbers of unstimulated or gemcitabine-treated cells were mixed with Low-Gelling 
Agarose (Sigma, St. Louis, MO, USA) at a final concentration of 0.3%. The agarose was 
allowed to solidify for 30 min at 4°C and DMEM supplemented as above was added in each 
well. Samples were incubated at 37°C for 10 days with medium change every 3 days. 
Samples were then stained for 30 min at room temperature with a solution containing 0.05% 
crystal violet followed by three washing steps with H/S.  
 
siRNA transfection studies 
SMA cells were transfected with Cy5-labeled mouse UDP-glucose ceramide 
glucosyltransferase siRNA or Cy5-labeled AllStars Negative Control siRNA (both from 
Qiagen, Hilden, Germany) according to the protocol provided by the manufacturer. Samples 
were stimulated or not with 100 nM gemcitabine for the indicated times and stained with 
FITC-Annexin V or anti-ceramide antibodies, respectively, as described above. 
 
Statistical analysis  
Data were expressed as mean values and standard deviations (S.D.). Statistical analysis was 
performed employing one-way ANOVA test with Dunnett’s correction. P ≤ 0.05 was taken as 
the level of significance. 
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RESULTS 
 
To identify molecular mechanisms of tumor cell resistance to gemcitabine, SMA glioma cells 
were stimulated with clinically relevant concentrations of gemcitabine (100 nM) for 72 hours. 
The remaining attached cells were collected and maintained for another 48 hours under 
standard culture conditions in order to eliminate those which had not completed their 
apoptotic program within the initial 72 hours of stimulation. The resulting cells were 
designated SMA-GcbR. The procedure of obtaining resistant cells from the bulk population 
preceded each of our assays. 
  
We further characterized the resistance of SMA-GcbR cells by examining their colony-
forming ability upon gemcitabine stimulation. To this end, SMA and SMA-GcbR cells were 
incubated with 100 nM gemcitabine for 24 hrs. Equal numbers from the two cell types were 
seeded in soft agar and formation of colonies was assessed 10 days later. The results indicate 
that, in contrast to the SMA bulk population, the colony-forming ability of SMA-GcbR cells 
remains unaffected by gemcitabine treatment (Fig. 1a). To confirm the resistance of SMA-
GcbR population to gemcitabine treatment, SMA and SMA-GcbR cells, respectively, were 
stimulated with 100 nM gemcitabine and analysed for the subcellular localization of pro-
apoptotic molecule Bax. In viable cells, Bax is localized predominantly in the cytoplasm or is 
loosely associated with the mitochondrial compartment (x). Upon stimulation with different 
apoptotic stimuli, Bax is inserted into the mitochondrial membrane and signals initiation of 
the intrinsic apoptosis pathway (x). Our results show that a large number of SMA cells 
respond to gemcitabine treatment with Bax insertion into the mitochondria (Fig. 1b, upper 
panel); while significantly less SMA-GcbR cells display Bax mitochondrial localization (Fig. 
1b, lower panel). These data confirm the resistance of SMA-GcbR cells to Gemcitabine and 
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suggest that gemcitabine triggers the intrinsic apoptosis pathway in the SMA but not SMA-
GcbR population.  
Many studies demonstrated that ceramide plays a crucial role in signalling induced by 
apoptotic stimuli, including several chemotherapeutic drugs (x). Thus, we investigated 
whether ceramide levels are different in SMA-GcbR cells compared to the bulk population 
upon gemcitabine treatment. Initial studies on the bulk population showed that gemcitabine 
induces ceramide release as early as 2 hrs post treatment, followed by a strong accumulation 
of ceramide starting with 8 hrs post treatment (data not shown). We, therefore, stimulated 
SMA and SMA-GcbR cells with 100 nM gemcitabine and quantified ceramide levels at 8 and 
12 hours after treatment, respectively. The results demonstrate that gemcitabine induces a 
significantly weaker ceramide response in SMA-GcbR compared to SMA cells (Fig. 2). This 
indicates a correlation between resistance to gemcitabine and cellular ceramide levels, and 
suggests that the SMA-GcbR population may exhibit a defective or altered ceramide 
metabolism. 
 
Ceramide can be produced either de novo, via activation of ceramide synthase, or following 
sphingomyelin cleavage mediated by acid, neutral or alkaline sphingomyelinases (x). Our 
group has recently demonstrated that glioma cells transfected to overexpress acid 
sphingomyelinase become sensitive to gemcitabine-induced cell death (x), which argues that 
the increase in ceramide levels observed after gemcitabine treatment may occur via activation 
of the acid sphingomyelinase. We, therefore, examined whether gemcitabine stimulation leads 
to activation of the acid sphingomyelinase in SMA cells. Furthermore, we inquired whether 
the SMA-GcbR population responds differently regarding gemcitabine-induced acid 
sphingomyelinase activation. To this end, SMA and SMA-GcbR cells were stimulated with 
100 nM gemcitabine and intrinsic acid sphingomyelinase activity was determined at different 
times post treatment. The results demonstrate that gemcitabine treatment leads to activation of 
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acid sphingomyelinase in SMA cells (Fig. 3a). SMA-GcbR responded with a similar pattern 
of acid sphingomyelinase activation (Fig. 3a), which suggests that resistance of these cells to 
gemcitabine-induced cell death is probably not caused by a defect in ceramide production 
pathways. 
 
To further elucidate mechanisms of the altered ceramide metabolism in resistant glioma cells 
compared to the bulk population, SMA and SMA-GcbR cells were stimulated with exogenous 
sphingomyelinase and ceramide levels were biochemically quantified at different times post 
treatment. The results indicate that exogenous sphingomyelinase induces a strong ceramide 
increase at 30 min post treatment in both populations (Fig. 3b). However, while SMA cells 
maintained high ceramide levels until 2 hour post treatment, SMA-GcbR cells presented 
significantly weaker ceramide levels already at 1 hour post treatment (Fig. 3b). These data 
demonstrate that the two cell types have different kinetics of ceramide metabolism and 
propose an involvement of ceramide consumption pathways in SMA-GcbR resistance to 
gemcitabine stimulation. 
The two main pathways of ceramide consumption are mediated via ceramidases, which 
convert ceramide to sphingosine, or via ceramide glucosyltransferase, which leads to 
glucosylceramide formation (x).  Next, we examined the biological significance of ceramide 
consumption regarding the response of resistant cells to gemcitabine treatment. To this end, 
SMA-GcbR cells were incubated with 75 µM NOE or 10 µM PPMP in the presence or 
absence of 100 nM gemcitabine and colony-formation assays were performed as described 
above. PPMP is a pharmacological compound known to inhibit glucosylceramide synthesis 
(x), while NOE has been described to induce ceramide accumulation by blocking the acid 
ceramidase (x). Our results show that co-treatment of SMA-GcbR cells with PPMP and 
gemcitabine greatly reduced the number of colonies, which was otherwise unaffected by 
gemcitabine alone (Fig. 4a). Since NOE did not significantly sensitize the SMA-GcbR 
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population to gemcitabine treatment (Fig. 4a), our data indicate a predominant role of 
glucosyltransferase- mediated ceramide consumption in SMA-GcbR resistance to therapy. 
Thus, we investigated the effect of PPMP on gemcitabine-induced apoptosis. We, therefore, 
stimulated SMA and SMA-GcbR cells with gemcitabine in the presence or absence of PPMP 
and determined cell death 48 hours later by annexin-V/propidium iodide staining. FACS 
analysis indicated that SMA cells presented a high percentage of apoptosis with gemcitabine 
alone and that addition of PPMP did not significantly amplify death in these cells (Fig. 4b). 
However, we observed a clear increase in SMA-GcbR cell death upon co-treatment with 
gemcitabine and PPMP (Fig. 4b) confirming the colony-formation assays (Fig. 4a). Control 
experiments were performed to assess the effect of PPMP on gemcitabine-induced ceramide 
levels. SMA and SMA-GcbR cells were stimulated with gemcitabine in the presence or 
absence of PPMP, respectively, and cellular ceramide levels were assessed 8 hours later by 
FACS analysis of cells labelled with Cy5-coupled anti-ceramide antibodies. The results show 
a significant increase in ceramide levels of the resistant cells upon co-treatment with 
gemcitabine and PPMP (Fig. 4c). These data suggest that the effect of PPMP regarding 
inhibition of colony formation and promotion of cell death, respectively, in SMA-GcbR cells 
upon gemcitabine treatment may be mediated by permitting accumulation of ceramide in 
these cells. 
 
To confirm the involvement of glucosyltransferase pathway in cellular resistance to 
gemcitabine treatment, we transfected SMA-GcbR cells with Cy5-labelled small interfering 
RNA (siRNA) targeted against murine glucosyltransferase. Cells were stimulated with 100 
nM gemcitabine and apoptosis was determined by FITC-annexin-V staining 48 hours later. 
Double fluorescence FACS measurements revealed a significantly higher number of annexin-
V positive cells in the SMA-GcbR population transfected with glucosyltransferase siRNA 
compared to SMA-GcbR cells transfected with negative control siRNA (Fig. 5a). These data 
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demonstrate that specific inhibition of glucosyltransferase restores SMA-GcbR sensitivity to 
gemcitabine treatment. Control experiments were performed to determine the effect of 
glucosyltransferase specific inhibition regarding gemcitabine-induced ceramide cellular 
levels.  Glucosyltransferase siRNA- or negative control- transfected SMA-GcbR cells were 
stimulated with gemcitabine and cellular ceramide levels were assessed 8 hours later by 
FACS analysis of cells labelled with Cy3-coupled anti-ceramide antibodies. The results show 
that only SMA-GcbR cells transfected with glucosyltransferase siRNA respond with an 
accumulation of ceramide upon gemcitabine treatment, while cells transfected with negative 
control siRNA did not significantly change the levels of cellular ceramide (Fig. 5b). These 
data indicate that specific inhibition of glucosylceramide results in accumulation of ceramide 
in gemcitabine-resistant cells, which restores gemcitabine-induced cell death. 
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DISCUSSION 
 
Resistance of tumor cells to chemotherapy constitutes a major problem in clinical oncology 
and patient treatment. Here, we present evidence for a critical function of cellular ceramide 
levels in the response of glioma cells to gemcitabine. We demonstrate that gemcitabine 
treatment triggers activation of the acid sphingomyelinase and ceramide release. While the 
bulk population of glioma cells accumulates ceramide in response to gemcitabine and dies, 
the resistant cells maintain their ceramide levels low and survive. Pharmacological or genetic 
inhibition of the glucosyltransferase pathway in the resistant population results in cellular 
accumulation of ceramide upon gemcitabine treatment and rescues death. Thus, our data 
suggest that consumption of ceramide via the glucosyltransferase pathway might be an 
important component of glioma cell resistance to chemotherapy. 
 
Many studies focused on clarifying the mechanisms of chemotherapy resistance in different 
types of cancer. Since numerous problematical factors are associated with examining such 
mechanisms in vivo, chemotherapy resistance has been mainly investigated utilizing cancer 
cell lines with different sensitivities to the respective drug. The most common method of 
obtaining chemotherapy-resistant cells is by continuous or intermittent exposure of the 
parental cell line to a certain drug, which is often applied in steadily increasing concentrations 
for long periods of time. This technique leads, however, to a progressively-acquired 
chemotherapy resistance which may be a consequence of genetic events that do not 
necessarily match the intrinsic resistance mechanisms of the primary tumors. In the present 
study we employed murine glioma cells selected for resistance after only one cycle of 
stimulation with clinically relevant doses of gemcitabine. Furthermore, the parental cells have 
been pre-sorted for tumorigenicity by allowing tumor formation in a VM/Dk mouse. Thus, 
our model may reflect more accurately the in vivo situation.  
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 Accumulating evidence reveal ceramide as a major player in signalling triggered by a variety 
of stimuli. Ceramide has been shown to be released upon stimulation with members of the 
TNF family of ligands and receptors (x), irradiation (x), pathogens (x) and several 
chemotherapeutic drugs (x). Once generated, ceramide may mediate signalling via clustering 
of receptors onto the plasma membrane (x), or via regulation of different intracellular 
molecules (x).  
Ceramide can be generated de novo, via activation of ceramide synthase, or by sphingomyelin 
cleavage following activation of sphingomyelinases (x). The main ceramide consumption 
pathways are mediated by ceramidases and glucosyltrasferases, which lead to formation of 
sphingosine, sphingosine-1-phosphate and glucosylceramide, respectively. An accumulation 
of cellular ceramide is usually associated with induction of cell death, while sphingosine-1-
phosphate and glucosylceramide are considered to be mainly anti-apoptotic (x). Thus, 
intrinsic down-regulation of ceramide production pathways and/or stimulation of ceramide 
consumption pathways would potentially confer resistance to the lethal effect of apoptosis-
inducing stimuli. Our studies investigating the activity of the ceramide-generating enzyme 
acid sphingomyelinase in response to gemcitabine showed no significant differences in the 
enzyme’s activation pattern between the bulk population and the resistant cells. Since acid 
sphingomyelinase was shown to be the enzyme responsible for ceramide generation upon 
gemcitabine treatment (x) our results seem to exclude a defect in ceramide production 
pathways as the mechanism responsible for glioma resistance to chemotherapy. Furthermore, 
our studies employing exogenous sphingomyelinase demonstrate a rapid decrease of 
sphingomyelinase-induced ceramide levels in the resistant population also indicating an 
upregulation of  ceramide consumption pathways in these cells. 
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Recent studies indicated a role of acid ceramidase-mediated ceramide consumption in prostate 
cancer cells resistance to chemotherapy (x). Our studies employing the acid ceramidase 
inhibitor NOE showed no effect of this drug regarding the colony forming capacity of SMA-
GcbR cells upon gemcitabine treatment. However, treatment of SMA-GcbR cells with 
gemcitabine in combination with the glucosyltransferase inhibitor PPMP greatly reduced the 
number of colonies. Furthermore, PPMP led to an increase in cellular ceramide levels and cell 
death following gemcitabine stimulation, suggesting an involvement of the 
glucosyltransferase –mediated ceramide consumption in glioma resistance to chemotherapy. 
Glucosyltransferase has been previously linked to multidrug resistance in a breast cancer cell 
model employing MCF-7 versus doxorubicin-resistant (AdrR) MCF-7 cells (x). However, 
recent findings rendered the MCF-7/AdrR-MCF-7 model questionable since the AdrR-MCF-7 
cell line was demonstrated to be an ovarian carcinoma and, therefore, unsuitable for 
comparison to the breast cancer cell line MCF-7 (x).  
 
Our studies employing small-interfering RNA (siRNA) against murine glucosyltransferase 
confirmed the sensitization of SMA-GcbR cells to gemcitabine-induced cell death via 
ceramide increase. Interestingly, the effect of glucosyltransferase siRNA regarding both cell 
death and cellular ceramide levels was slightly weaker compared to that of PPMP. Recent 
studies suggested the existence of an additional ceramide consumption pathway mediated by 
lysosomal phospholipase A2 (LPLA2) with the subsequent formation of 1-O-acylceramide (x). 
Furthermore, this enzyme was efficiently inhibited by compounds structurally related to 
PPMP, namely PDMP and P4 (x). It is, therefore, not excluded that the more potent effect of 
PPMP may be due to an additional inhibition of LPLA2; however, since most of the cells were 
sensitized by inhibition of the glucosyltransferase, the LPLA2 pathway would account only as 
a secondary mechanism regarding resistance of glioma cells to chemotherapy. 
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In conclusion, our study identifies glucosyltransferase-mediated ceramide consumption as a 
novel mechanism of glioma cell resistance to gemcitabine-induced death. The transfer of this 
concept to a clinical situation would predict that concomitant inhibition of glucosyltransferase 
may amplify the therapeutic potential of gemcitabine and, perhaps, of other chemotherapeutic 
agents that signal via ceramide. 
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 FIGURE LEGENDS 
 
Fig. 1: SMA-GcbR cells are resistant to gemcitabine stimulation 
(a) Treatment of SMA cells with 100 nM gemcitabine inhibits colony formation only in 
the SMA population, while SMA-GcbR cells are resistant. Coony formation was determined 
by soft agar clonogenic assay. The experiments were performed in sixplicate wells for each 
condition. Displayed is a typical result representative for four independent experiments. 
(b) SMA but not SMA-GcbR cells respond to gemcitabine treatment with insertion of Bax 
into the mitochondria. Cells were stimulated with 100 nM gemcitabine for 24 hrs, fixed, 
permeabilized, stained with Cy3-anti-Bax and FITC-anti-Tim23 antibodies and analysed by 
confocal microscopy. The results are representative for three studies with analysis of each 150 
cells/sample. 
 
Fig. 2: SMA-GcbR cells do not respond to gemcitabine with an increase of ceramide 
levels 
(a) SMA or SMA-GcbR cells were stimulated with 100 nM gemcitabine for the indicated 
times and the levels of ceramide were determined by DAG-kinase assay, which 
phosphorylates ceramide to ceramide-1-phosphate in the presence of [32P]-gamma-ATP. The 
results show that SMA-GcbR fail to accumulate ceramide upon treatment with gemcitabine. 
Displayed is a typical result representative for three independent experiments. 
 
Fig. 3: Ceramide consumption is altered in SMA-GcbR cells 
(a) Treatment of SMA or SMA-GcbR cells with 100 nM gemcitabine results in similar 
activation of acid sphingomyelinase (ASM) in both populations. ASM activation was 
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determined by degradation of [14C]-labeled sphingomyelin to [14C]-labeled 
phosphorylcholine. The data are the mean ± S.D. of three independent experiments. 
(b) Exogenous sphingomyelinase-induced ceramide is rapidly consumed in SMA-GcbR 
cells, while ceramide accumulates in sensitive SMA cells. SMA or SMA-GcbR cells were 
stimulated with 2 units/ml of exogenous sphingomyelinase for the indicated times and the 
levels of ceramide were determined by DAG-kinase assay, which phosphorylates ceramide to 
ceramide-1-phosphate in the presence of [32P]-gamma-ATP. Displayed is a typical result 
representative for three independent experiments. 
 
Fig. 4: Glucosyltransferase-mediated ceramide consumption mediates resistance of 
SMA-GcbR to gemcitabine 
(a) Inhibitors of glucosyltransferases reduce colony-formation ability of SMA-GcbR cells 
upon treatment with gemcitabine. SMA-GcbR cells were stimulated with 100 nM gemcitabine 
in the presence or absence of PPMP or NOE. Soft-agar clonogenic assays were performed in 
sixplicate wells for each condition. Number of colonies was taken as average of the six 
replicates from each experiment. The data are the mean ± S.D. of three independent 
experiments. Significant differences (P≤0.05, ANOVA) between stimulated and unstimulated 
samples are labeled by an asterisk *. 
(b) Pharmacological inhibitors of glucosyltransferase sensitize SMA-GcbR cells to 
gemcitabine-induced cell death. SMA or SMA-GcbR cells were stimulated with 100 nM 
gemcitabine in the presence or absence of PPMP. Cell death was determined 48 hrs later by 
flow cytometry analysis of Annexin-V/propidium iodide (PI)-stained cells. The results are the 
mean ± S.D. of four independent experiments. Significant differences (P≤0.05, ANOVA) 
between stimulated and unstimulated samples are labeled by an asterisk *. 
(c) Pharmacological inhibition of glucosyltransferase restores ceramide accumulation in 
SMA-GcbR cells after gemcitabine treatment. SMA or SMA-GcbR cells were stimulated with 
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100 nM gemcitabine in the presence or absence of PPMP. Ceramide was determined 8 hrs 
later by flow cytometry analysis of cells stained with Cy5-coupled anti-ceramide antibodies. 
Data are represented as fold increase in the mean intensity of fluorescence (MIF) compared to 
the untreated sample, which was set at 1. The results are the mean ± S.D. of three independent 
experiments. Significant differences (P≤0.05, ANOVA) between stimulated and unstimulated 
samples are labelled by an asterisk *. 
 
Fig. 5: Specific inhibition of glucosyltransferase sensitizes SMA-GcbR to gemcitabine-
induced ceramide increase and cell death 
(a) Genetic inhibition of glucosyltransferase by transfection with siRNA restores death of 
SMA-GcbR upon gemcitabine treatment. Cells were transfected with Cy5-glucosyltransferase 
siRNA or Cy5-negative control siRNA for 16 hrs followed by 48 hrs stimulation with 100 nM 
gemcitabine. Cells were stained with FITC-annexin-V and analysed by flow cytometry. 
Apoptosis was determined in the Cy5-positive population as percentage of annexin-positive 
cells. The results are the mean ± S.D. of three independent experiments. Significant 
differences (P≤0.05, ANOVA) between gemcitabine-stimulated and -unstimulated samples 
are labeled by an asterisk *. 
(b) SMA-GcbR cells transfected with glucosyltransferase siRNA accumulate ceramide 
upon gemcitabine treatment. Cells were transfected with Cy5-glucosyltransferase siRNA or 
Cy5-negative control siRNA for 16 hrs followed by 8 hrs stimulation with 100 nM 
gemcitabine. Samples were stained with Cy3-coupled anti-ceramide antibodies and ceramide 
levels were determined in the transfected cells (Cy5-positive) by flow cytometry analysis. 
Data are represented as fold increase in the mean intensity of fluorescence (MIF) compared to 
the negative-control siRNA sample, which was set at 1. The results are the mean ± S.D. of 
three independent experiments. Significant differences (P≤0.05, ANOVA) between 
gemcitabine-stimulated and -unstimulated samples are labelled by an asterisk *. 
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